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Abstract
Background: Atherosclerosis is now recognized as a chronic inflammatory disease. Angiotensin II (Ang II) is a critical 
factor in inflammatory responses, which promotes the pathogenesis of atherosclerosis. Placental growth factor (PlGF) is 
a member of the vascular endothelial growth factor (VEGF) family cytokines and is associated with inflammatory 
progress of atherosclerosis. However, the potential link between PlGF and Ang II has not been investigated. In the 
current study, whether Ang II could regulate PlGF expression, and the effect of PlGF on cell proliferation, was 
investigated in human vascular endothelial cells (VECs) and smooth muscle cells (VSMCs).
Results: In growth-arrested human VECs and VSMCs, Ang II induced PlGF mRNA expression after 4 hour treatment, and 
peaked at 24 hours. 10-6 mol/L Ang II increased PlGF protein production after 8 hour treatment, and peaked at 24 hours. 
Stimulation with Ang II also induced mRNA expression of VEGF receptor-1 and -2(VEGFR-1 and -2) in these cells. The 
Ang II type I receptor (AT1R) antagonist blocked Ang II-induced PlGF gene expression and protein production. Several 
intracellular signals elicited by Ang II were involved in PlGF synthesis, including activation of protein kinase C, 
extracellular signal-regulated kinase 1/2 (ERK1/2) and PI3-kinase. A neutralizing antibody against PlGF partially inhibited 
the Ang II-induced proliferation of VECs and VSMCs. However, this antibody showed little effect on the basal 
proliferation in these cells, whereas blocking antibody of VEGF could suppress both basal and Ang II-induced 
proliferation in VECs and VSMCs.
Conclusion: Our results showed for the first time that Ang II could induce the gene expression and protein production 
of PlGF in VECs and VSMCs, which might play an important role in the pathogenesis of vascular inflammation and 
atherosclerosis.
Background
Atherosclerosis is now considered to be a chronic inflam-
matory process which may ultimately lead to acute myo-
cardial infarction, cerebrovascular and peripheral
vascular diseases [1,2]. Plenty of data suggest that the ren-
nin-angiotensin system (RAS) plays an important role in
the development of many cardiovascular diseases, includ-
ing the pathophysiological process of atherosclerosis
[3,4]. Many studies have shown that inhibition of the RAS
could reduce inflammation and oxidative stress [5].
Angiotensin II (Ang II), one of the major effectors of the
RAS, is a cytokine that regulates cell growth, inflamma-
tion and fibrosis contributing to the progression of vascu-
lar damage [4,6,7]. Ang II participates in atherosclerosis
pathogenesis by inducing inflammation and apoptosis,
facilitating absorption of oxidative low density lipopro-
tein, generating oxygenic radicals and impacting fibrinol-
ysis function [7]. The physiological actions of Ang II are
mediated via its type 1 receptor (AT1R) and type 2 recep-
tor (AT2R), which are expressed under different develop-
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mental, tissue-specific, and disease-specific conditions
[8,9]. It has been shown that Ang II activates NF-κB, a key
component of inflammation, in vascular smooth muscle
cells (VSMCs)[10]. However, the exact mechanism of
Ang II-mediated inflammation in vascular endothelial
cells (VECs) or VSMCs is still largely unclear.
Recently, Placenta growth factor (PlGF) has emerged as
a key factor in vascular inflammation and progression of
atherosclerosis [11-13]. PlGF is a member of the vascular
endothelial growth factor (VEGF) family cytokines and is
associated with inflammation and with pathologic angio-
genesis [14-16]. It is a polypeptide growth hormone that
binds to Flt-1-receptor (VEGFR-1), neuropilin-1 (NRP1)
and neuropilin-2 (NRP2) receptors, but not to VEGF-
receptor type 2 (VEGFR-2)[14]. Recent study has shown
that PlGF is required for macrophage infiltration in early
atherosclerotic lesions in apolipoprotein E-deficient mice
[11]. PlGF has atherogenic properties including recruit-
ment and adhesion of monocytes, induction the produc-
tion of proteinase, and thrombus formation through
stimulating tissue factor secretion [12]. It is up-regulated
in early and advanced atherosclerotic lesions, acting as a
primary inflammatory instigator of atherosclerotic
plaque instability[12]. Moreover, it has been recognized
as an independent biomarker of adverse outcome in
patients with acute coronary syndromes (ACS) [13,17].
As a more specific marker of vascular inflammation,
PlGF might be considered for risk stratification of
patients with ACS[13]. The PlGF expression can be
induced by hypoxia and various pro-inflammatory stim-
uli [18]. This induction is mediated via NF-kappa B and
metal response transcription factor-1(MTF-1)[19]. How-
ever, the regulation of PlGF expression in vascular cells,
and its mechanisms of action have received little atten-
tion in atherosclerosis research.
Because PlGF plays a role in initiation and progression
of atherosclerosis, it is interesting to examine the poten-
tial interaction between Ang II and PlGF. However, the
connection between Ang II and PlGF expression in vas-
cular cells has not been studied. In this study, we exam-
ined the effect of Ang II on the PlGF expression in both
human VECs and VSMCs. Previously, the HUVEC-
derived endothelial cell line (EA.Hy 926) [20,21] and
human umbilical artery smooth muscle cells
(HUASMCs)[22,23] have been characterized as models of
investigating the functions of VECs and VSMC, respec-
tively. EA.Hy 926 endothelial cells and HUASMCs were
used in the present study.
Results
Angiotensin II increases PlGF mRNA and protein levels in 
both EA.Hy 926 cells and HUASMCs
The human umbilical vein endothelial cell-derived cell
line EA.Hy 926 was used in this study. As an established
cell line, EA.Hy 926 cell is homogenous compare to the
variable primary cells from individual donors.
To determine whether Ang II modulates PlGF gene
expression in VECs, EA.Hy 926 endothelial cells were
treated with different concentrations of Ang II. Total
RNA was isolated at various time points (up to 48 hours).
After 4 hour treatment, real-time quantitative RT-PCR
revealed that 10-6 mol/L concentration of Ang II induced
the expression of PlGF above basal levels, and the induc-
tion was peaked at 24 hours after treatment (Figure 1A).
The induction of PlGF mRNA by Ang II was best at 10-6
mol/L and was less effective at 10-7 mol/L or 10-5 mol/L
(Figure 1B). Standard concentration of 10-6 mol/L Ang II
was used for all further experiments. Similarly, Ang II at
10-6 mol/L also led to a time-dependent increase of PlGF
mRNA expression in HUASMCs (Figure 1A).
Next, we examined the Ang II- induced change of PlGF
protein level in EA.Hy 926 endothelial cells and
HUASMCs. Cells were exposed to Ang II treatment for
indicated times. Subsequently, the secretion of PlGF in
the culture media was measured by ELISA. Under serum-
starvation condition, EA.Hy 926 cells secreted low level
of PlGF (~ 12 pg/mL). Treatment with Ang II for 8, 24 or
48 hours evoked significant secretion of PlGF, as com-
pared to the untreated cells (Figure 1C). Similarly, the
growth-arrested HUASMCs released low level of PlGF
protein in the cell culture supernatant. When HUASMCs
were treated with Ang II for 24 or 48 hrs, the PlGF pro-
duction was significantly higher than that in untreated
cells (Figure 1C).
The expression of PlGF was also analyzed by immuno-
fluorence technique. Only weak PlGF fluorescence inten-
sity was observed in growth-arrested EA.Hy 926 cells and
HUASMCs. Ang II stimulation for 24 hours significantly
increased the cytoplasmic PlGF fluorescence intensity in
both cell types (Figure 1D).
Taken together, our data indicated that Ang II
increased PlGF mRNA and protein production in EA.Hy
926 cells and HUASMCs.
Angiotensin II increases VEGFR-1 and VEGFR-2 mRNA 
expression in both EA.Hy 926 cells and HUASMCs
VEGF is a the major initiator of angiogenesis and its
actions are mediated via two major receptors, VEGFR-
1(Flt-1) and VEGFR-2(KDR) [24,25]. VEGF is an essential
mediator in Ang II-induced vascular inflammation and
structural changes through its proinflammatory actions
[24]. In order to investigate the possible role of VEGF and
its receptors in our experimental model, we first mea-
sured the release of VEGF in the culture supernatant of
these cells. Our results showed that treatment with Ang II
significantly increased the release of VEGF in the cell cul-
ture supernatant (Figure 2A). We also examined the
VEGFR-1 and VEGFR-2 gene expression by real-timePan et al. BMC Cell Biology 2010, 11:36
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Figure 1 Angiotensin II increases PlGF mRNA expression (A, B) and protein production (C, D) in EA.Hy 926 endothelial cells and HUASMCs. 
Growth-arrested EA.Hy 926 cells and HUASMCs were stimulated with Angiotensin II (10-6 mol/L) for different durations. (A) Quantitative RT-PCR (Q-
PCR) results. Total RNA was isolated from cells. After reverse transcription, they were subjected to quantitative PCR analysis to determine PlGF mRNA 
level. Graph is representative of relative PlGF mRNA levels in the various conditions. Experiments were performed five times with the similar results (n 
= 5 in each group). * indicates P < 0.05 vs control EA.Hy 926 cells or HUASMCs. (B) Induction of PlGF mRNA expression is Ang II concentration-depen-
dent. * indicates P < 0.05 vs control EA.Hy 926 cells or HUASMCs. (C) Release of PlGF protein measured by ELISA. Cells were incubated with Ang II (10-
6 mol/L) for 8, 24 or 48 h, and PlGF protein released into cell culture media was measured by ELISA (n = 3 in each group). * indicates P < 0.05 vs control 
EA.Hy 926 cells or HUASMCs. (D) Expression of PlGF protein detected by immunofluorescence assay. Immunofluorescence detecting of PlGF expres-
sion in untreated control cells, and cells stimulated with Ang II (10-6 mol/L) for 24 hours (original magnification of 200 ×). Mean optical density (MOD) 
of PlGF staining was measured on the images by using the ImageJ software. The figure shows one of three similar experiments. * P < 0.05 vs control 
EA.Hy 926 cells or HUASMCs.
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PCR. W e showed that the expression of both VEGFR-1
and -2 mRNA were induced upon Ang II stimulation.
This induction of VEGFR gene expression was abolished
by the AT1R blocker, Losartan (Figure 2B and 2C). Our
results confirmed that VEGF and its receptors might be
involved in Ang II actions in VECs and VSMCs.
Angiotensin II increases PlGF expression via AT1R in both 
EA.Hy 926 cells and HUASMCs
In VECs and VSMCs, Ang II acts through two specific
receptors, AT1R and AT2R [8]. To evaluate the roles of the
two receptors in the Ang II-induced PlGF expression,
EA.Hy926 cells and HUASMCs were pre-treated with the
two receptor antagonists, and then incubated with Ang
II. The AT1R antagonist Losartan caused a significant
d e c r e a s e  i n  A n g  I I - i n d u c e d  P l G F  e x p r e s s i o n  a t  b o t h
mRNA and protein levels (Figure 3), whereas the AT2R
antagonist PD 123319 had no effect, suggested that Ang
II-inuced PlGF up-regulation was mediated through its
AT1 receptor.
Signaling mechanisms involved in Angiotensin II-induced 
PlGF gene and protein production
Ang II, via AT1R, activates several intracellular signaling
pathways, including PKC, ERK1/2 and PI-3K [26-28]. To
evaluate the roles of downstream signaling in the Ang II-
induced PlGF expression, EA.Hy926 cells and HUASMCs
were pre-treated with kinase inhibitors Calphostin C,
Figure 2 Angiotensin II increases VEGF release (A) and VEGFR-1 
and -2 mRNA expressions (B, C) in EA.Hy 926 endothelial cells and 
HUASMCs. (A) Release of VEGF in the cell culture media measured by 
ELISA. Growth-arrested cells were incubated with Ang II (10-7, 10-6 and 
10-5 mol/L) for 8 hrs, 24 hrsor 48 hrs, and VEGF protein released into cell 
culture media was measured by ELISA (n = 3 in each group). * indicates 
P < 0.05 vs control EA.Hy 926 cells or HUASMCs. (B) Real-time PCR re-
sults: Ang II induced VEGFR-1 mRNA expression in both EA.Hy 926 en-
dothelial cells and HUASMCs. * indicates P < 0.05 vs control EA.Hy 926 
cells or HUASMCs. # indicates P < 0.05 vs cells treated with Ang II. (C) 
Real-time PCR results: Ang II induced VEGFR-2 mRNA expression in 
both EA.Hy 926 endothelial cells and HUASMCs. * indicates P < 0.05 vs 
control EA.Hy 926 cells or HUASMCs. # indicates P < 0.05 vs cells treated 
with Ang II.
Figure 3 Angiotensin II induces PlGF mRNA (A) and protein levels 
(B) via AT1 in EA.Hy 926 endothelial cells and HUASMCs. Cells were 
pretreated for 30 min with 10-6 mol/L Losartan (AT1R antagonist) or -6 
mol/L PD123319 (AT2R antagonist) and then stimulated with 10-6 mol/
L Ang II for 24 hours. (A) Q-PCR results: PlGF mRNA expression was as-
sayed by Q-PCR. Experiments were performed five times with the sim-
ilar results (n = 5 in each group). * indicates P < 0.05 vs control EA.Hy 
926 cells or HUASMCs. # indicates P < 0.05 vs cells treated with Ang II. 
(B) PlGF protein production in the cell culture media was measured by 
ELISA (n = 3 in each group). * indicates P < 0.05 vs control EA.Hy 926 
cells or HUASMCs. # indicates P < 0.05 vs cells treated with Ang II.
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PD98059 or Wortmannin. By using quantitative RT-PCR
and ELISA, subsequent signal inhibition experiments
revealed that treatment with Calphostin C, PD98059, and
Wortmannin significantly decreased the Ang II-induced
PlGF mRNA and protein expression in the both cell types
(Figure 4). These data suggest that, PKC, ERK1/2 and PI-
3K all involved in stimulating PlGF expression by Ang II.
Role of PlGF in the Angiotensin II-induced proliferation of 
EA.Hy 926 cells and HUASMCs
In order to examine if PlGF or VEGF played a role in Ang
II-induced proliferation, we used MTT incorporation
assay [29,30] to study the proliferation of growth-arrested
EA.Hy 926 cells and HUASMCs followed by (1) Ang II
treatment, or (2) co-treatment of Ang II and a neutraliz-
ing antibody against to PlGF or VEGF (10 or 20 μg/mL),
or (3) administration of the blocking antibody for PlGF or
VEGF alone for 24 h.
Figure 5 shows that, similar to other reports[31,32] in
which administration of Ang II stimulated the prolifera-
tion of cultured vascular cells, treatment with Ang II (10-6
mol/L) for 24 hours significantly increased EA.Hy 926
cell proliferation by 138% compared to the control; and
increased HUASMCs proliferation by 91.6%. A neutraliz-
ing antibody specific to PlGF inhibited Ang II-induced
proliferation in EA.Hy 926 cells (40.9% inhibition), and to
a less extent, in HUASMCs (26.8% inhibition) (Fig. 5A).
Moreover, a neutralizing antibody specific to VEGF
inhibited Ang II-induced proliferation in EA.Hy 926 cells
(43.3% inhibition), and to a less extent, in HUASMCs
(35.5% inhibition) (Fig 5B). Ang II-stimulated cell prolif-
eration was suppressed by the simultaneous administra-
Figure 4 Molecular mechanisms involved in Angiotensin II-in-
duced PlGF upregulation in EA.Hy 926 cells and HUASMCs. (A) Ef-
fects of different inhibitors on the PlGF mRNA expression induced by 
Ang II by using Quantitative RT-PCR. Cells were pretreated with differ-
ent inhibitors for 30 mins and stimulated with Ang II (10-6 mol/L) for 24 
hours, and PlGF mRNA expression was assayed by Q-PCR (n = 3 in each 
group). * P < 0.05 vs control cells. # P < 0.05 vs cells treated with Ang II 
alone. (B) Effects of different inhibitors on the PlGF protein expression 
induced by Ang II detected by using ELISA. PlGF protein contents in 
the cell culture media were assayed by ELISA (n = 3 in each group). * P 
< 0.05 vs control cells. # P < 0.05 vs cells treated with Ang II alone.
Figure 5 PlGF and VEGF is involved in Angiotensin II-induced 
proliferation of cultured EA.Hy 926 cells and HUASMCs. Quiescent 
cells were treated with Ang II (10-6 mol/L), Ang II (10-6 mol/L) and Losar-
tan (10-6 mol/L), Ang II (10-6 mol/L) and the specific neutralizing anti-
body to PlGF(A) or VEGF (B)(20 μg/mL) for 24 hours, followed by the 
assessment of cell proliferation by MTT assay. Each value is the mean ± 
SD of 5 separate determinations. * indicates P < 0.05 vs control cells. # 
indicates P < 0.05 vs cells treated with Ang II. Ab-PlGF: the specific neu-
tralizing antibody against PlGF. Ab-VEGF: the blocking antibody to 
VEGF.
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tion of the AT1R blocker Losartan (69.8% and 62.2%
inhibition rate in EA.Hy 926 and HUASMCs respec-
tively). However, administration of blocking antibody to
PlGF alone had no effect on the proliferation in these vas-
cular cells, while the blocking antibody to VEGF alone
could significantly suppressed the proliferation rate in
both EA.Hy 926 cells and in HUASMCs. Our data indi-
cated that PlGF was involved in Ang II-induced prolifera-
tion of EA.Hy 926 cells and HUASMCs, whereas VEGF
was implicated in both basal and Ang II-induced prolifer-
ation in these cells.
Discussion and Conclusions
In the present study, the potential correlation between
Ang II and PlGF was investigated in cultured EA.Hy 926
endothelial cells and in HUASMCs. The major findings of
this study are: (1) Ang II, via AT1R, induces PlGF gene
expression and protein secretion in both VECs and
VSMCs; (2) Ang II increases VEGFR-1 and -2 gene
expression in these vascular cells; (3) multiple signaling
pathways, including PKC, ERK1/2 and PI3-K, are
in volved in t his Ang II-induced P lGF upr egula tion; (4)
blockade of PlGF results in the inhibition of Ang II-
induced proliferation in these cells, whereas blockade of
VEGF leads to inhibition of both basal and Ang II-elicited
proliferation. Our observations established a role of PlGF
in mediating Ang II-induced proliferation in vascular
endothelial cells and vascular smooth muscle cells. In
addition, our results suggested that inhibition of PlGF or
VEGF might be useful in preventing abnormal VEC or
VSMC proliferation evoked by Ang II.
Numerous studies suggest that the renin-angiotensin
system (RAS) contributes to the pathogenesis of athero-
sclerosis [4,7]. Angiotensin II, the principal effecter of the
RAS, is not only a vasoactive hormone, but also a
cytokine that regulates cell proliferation, inflammation
and fibrosis. Ang II elicits the inflammatory response by
stimulating the production of chemokines, cytokines, and
adhesion molecules [10]. Recent study demonstrated that
Ang II induced vascular endothelial cell proliferation by
increasing the expression of the angiogenic factor VEGF
[31]. Consistent with previous reports [24,25,31], we
observed that Ang II increased VEGF and its two recep-
tors expression in our experimental model. Meanwhile,
o u r  d a t a  p r o v i d e d  d i r e c t  e v i d e n c e  t h a t ,  i n  v a s c u l a r
endothelial cell and smooth muscle cells, Ang II, via its
AT1 receptor, could up-regulate PlGF expression. These
results suggested that Ang II might participate in the reg-
ulation of pathological angiogenesis.
Ang II acts through binding to its specific AT1 and AT2
receptors, which are seven transmembrane glycoproteins
with 30% sequence similarity[8]. The AT1R is a classical G
protein-coupled receptor, whereas AT2R often antago-
nizes the effects of signaling through the AT1R[9]. Many
AT1R-induced growth responses are mediated by trans-
activation of growth factor receptors. AT1 receptor regu-
lates cell proliferation, cytokines production and some
pathological processes, including Ang II-induced hyper-
tension and cardiac hypertrophy. Although AT1 receptor
mediates most of the recognized cardiovascular effects of
Ang II, the AT2 receptor contributes to the regulation of
blood pressure and renal function. Our data demon-
strated that, in cultured EA.Hy 926 endothelial cells and
HUASMCs, Ang II increased PlGF expression and syn-
thesis via its AT1 receptor.
Several pathways, e.g. PKC [26], ERK1/2 [7,26,33], and
PI3K/Akt [34], involved in AT1R activation. Using spe-
cific inhibitors, the present study showed that Ang II acti-
vated PKC, ERK1/2 and PI-3K pathways. The activation
of all these pathways contributed to PlGF up-regulation
in EA.Hy 926 endothelial cells and HUASMCs.
The induction of PlGF gene expression by Ang II may
be of considerable clinical significance, especially in vas-
cular inflammation and atherosclerosis. Pro-inflamma-
tory cytokines play a crucial role of in the development of
atherosclerosis and plaque instability. Quiescent vascular
endothelial cells only release minimal amounts of PlGF.
In contrast, activated endothelial cells could produce
large amounts of PlGF[35]. Previous studies demon-
strated that PlGF activated monocytes and increased the
expression of tumor necrosis factor-α(TNF-α), interleu-
kin-1β (IL-1β), and monocyte chemotactic protein-
1(MCP-1) in monocytes[36,37]. Consequently, when
stimulated by Ang II, vascular endothelial cells produce
PlGF, which activates neutrophils and monocytes, results
in their adherence to endothelial cells. This might trigger
the pathophysiological changes observed in atherosclero-
sis. Our results indicated that, the administration of
PlGF-neutralizing antibody significantly inhibited the
Ang II-dependent proliferation of vascular endothelial
cells, suggested that PlGF might be a down-stream angio-
genic mediator of RAS. The neutralizing antibodies of
PlGF or VEGF are less effective in inhibiting cell prolifer-
ation than the small molecule inhibitor of AT1R, since
other effects are involved besides VEGF/PlGF produc-
tion. It has been largely demonstrated that the Ang II-
induced VSMC proliferation is mediated by PDGF and
Egr-1 [38,39]. And the AT1R blocker might be useful as
an anti-angiogenic agent.
It has been recognized that VSMC proliferation within
the vessel wall is an important pathogenic feature in the
development of atherosclerosis [40,41]. Ang II has been
implicated to play an important role in this cellular mech-
anism. When exposed to hypoxia (3% O2), the prolifera-
tion and contraction of VSMC were enhanced by PlGF
treatment [42]. Furthermore, recent study has shown thatPan et al. BMC Cell Biology 2010, 11:36
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PlGF expression in human atherosclerotic carotid
plaques is related to inflammation and clinical plaque
instability[12]. Present observations showed that Ang II
induced PlGF expression in VSMC, suggested a role of
PlGF in mediating VSMC proliferation induced by Ang II.
It has been shown that Ang II could stimulate the
expression of hypoxia inducible factor-1α (HIF-1α) [43],
and HIF-1α seems to be involved in the enhanced PlGF
expression stimulated by hypoxia [19]. The hypoxia-
inducible PlGF expression is mediated through NF-κB,
metal-regulatory transcription factor-1(MTF-1) and the
interaction between them [19]. Ang II-induced PlGF
expression might be mediated through the HIF-1α path-
ways. However, future studies in vascular cells are neces-
sary to determine the role of Ang II receptors and PlGF in
atherosclerosis.
In conclusion, PlGF might be one of the downstream
effectors up-regulated by Ang II in vascular diseases. Sev-
eral pathways, such as PKC and ERK 1/2 activation, seem
to be involved in the Ang II-induced PlGF expression in
vascular cells. PlGF also mediates Ang II-induced cell
proliferation in VECs and HUASMCs. Thus, our study
provides new insights into PlGF as one of the Ang II-
inducible genes. The link of PlGF to Ang II might be a




A human endothelial cell line (EA.Hy 926) was grown in
RPMI 1640 (GIBCO-BRL) supplemented with 10% FBS,
1% penicillin/streptomycin, 2 mmol/L L-glutamine and
1% HAT (Sigma, USA).
Primary cultures of HUASMCs were isolated from
freshly delivered umbilical cords by tissue explanting
method [22,23] and maintained in DMEM medium
(GIBCO-BRL) supplemented with 20% fetal bovine
serum (FBS) (Hyclone), 2 mmol/L L-glutamine, and 1%
penicillin-streptomycin. All cell cultures were maintained
in a humidified 5% CO2/95% air incubator at 37°C.
HUASMCs were identified by the specific marker of vas-
cular smooth muscle cell (α-smooth muscle actin, α-
SMA) immunofluorescence. The study was approved by
the medical ethics committee of the West China Hospital,
Sichuan University.
In all experiments, confluent EA.Hy 926 cells or
HUASMC cells at passage 4 to 8 were washed and incu-
bated with serum-free media for 24 hours. These cells
were treated with human angiotensin II (Ang II, 10-6 mol/
L) for different time points. In some experiments, cells
were pre-treated for 30 minutes with 10-7 mol/L Wort-
mannin, 10-6 mol/L Calphostin C, 10-6 mol/L PD98059,
10-6  mol/L Losartan (AT1R antagonist) or 10-6  mol/L
PD123319(AT2R antagonist), and then stimulated with
10-6 mol/L Ang II for different time points.
Quantitative reverse transcription PCR (Real-time RT-PCR)
The expression of PlGF gene was identified by quantita-
tive RT-PCR (Q-PCR) as reported earlier [44]. Total RNA
was extracted from HUASMCs or EA.Hy 926 cells using
TRIZOL reagent (Invitrogen, USA). Q-PCR was carried
out on an ABI Prism 7300 PCR Detection System
(Applied Biosystems, USA) with fluorescence dye SYBR
Green (SYBR Green Real-time PCR Master Mix,
TOYOBO, Japan). The sequences of the primers were as
follows: PlGF-F: 5'-GTT CAG CCC ATC CTG TGT CT-
3'; PlGF-R: 5'-CTT CAT CTT CTC CCG CAG AG-3'.
GAPDH-F: 5'-ACC ACA GT CCA TGC CAT CAC-3';
GAPDH-R: 5'-TCC ACC ACC CTG TTG CTG TA-3'.
VEGFR-1-F: 5'-ATC ATT CCG AAG CAA GGT GTG-3';
VEGFR-1-R: 5'-AAA CCC ATT TGG CAC ATC TGT-3'.
VEGFR-2-F: 5'-CAC CAC TCA AAC GCT GAC ATG
TA-3'; VEGFR-2-R: 5'-GCT CGT TGG CGC ACT CTT-
3'. The thermal cycling conditions were as following: 95°C
60 seconds, 40 cycles of 95°C for 15 seconds, 56°C for 15
seconds, 72°C for 45 seconds (data collection). Data anal-
ysis was carried out by ABI sequence detection software
using relative quantification. For quantification, the tar-
get sequence was normalized to the GAPDH mRNA lev-
els.
Quantification of PlGF and VEGF by ELISA
The PlGF or VEGF levels in the cell culture supernatant
were measured by a "sandwich" enzyme immunoassay
(Quantikine ELISA, R&D Systems, USA) according to
manufacture's instructions. Briefly, the samples were
added to 96-well plates coated with a specific monoclonal
antibody to PlGF or VEGF. The unbound protein was
washed three times, and an enzyme-linked polyclonal
antibody specific to PlGF or VEGF was added. The plates
were washed again for three times, and substrate solution
was added to the wells. After 30 min of incubation, stop
solution was added to each well. The amount of PlGF or
VEGF was determined by optical density of the samples
by comparison with the standards at 450 nm using an
ELISA reader (Bio-Rad Model 680, USA).
Detection PlGF protein expression by immunofluorescence
EA.Hy 926 cells or HUASMCs were plated onto cover-
slips in 6-well plates, growth arrested and treated with
Ang II at 10-6 mol/L concentration with or without other
compounds. After that, the cells on the glass slides were
then fixed and blocked as described before [31], followed
by exposed to the primary anti-PlGF antibody. The sec-
ond antibody was FITC-conjugated antibody and the cell
nuclei were stained with DAPI (Sigma-Aldrich). Images
were collected using an Eclipse TE2000-U fluorescentPan et al. BMC Cell Biology 2010, 11:36
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microscope system (Nikon, Japan) and analyzed with
ImageJ software from NIH Image to semi-quantitatively
determine the expression of PlGF protein in the cyto-
plasm of the cells.
Assessment of cell proliferation
The effect of Ang II and antagonists to PlGF or VEGF on
cell proliferation was determined by the 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay, as described previously[29]. Briefly, EA.Hy 926
cells or HUASMC cells were subcultured in 96-well plates
and incubated with serum-free medium for 24 hours.
Quiescent cultures were treated with the Ang II (10-6
mol/L), Ang II (10-6 mol/L) and Losartan (10-6 mol/L),
Ang II (10-6 mol/L) and the specific PlGF or VEGF neu-
tralizing antibody (10-20 μg/mL) for 24 hours. Twenty
microliters of MTT (15 mg/mL, Sigma, USA) was added
to each well and incubated for 4 h at 37°C. The culture
supernatant was discarded by aspiration and 150 μL of
dimethyl sulfoxide (DMSO, Sigma) was added for 10 min.
The light absorbance at 570 nm was detected using
ELISA reader (Bio-Rad Model 680, USA).
Statistical analysis
The experimental data were expressed as means ± SD.
Group means were compared by One-way ANOVA using
the statistical software program SPSS 10.0 for Windows
(Chicago, IL, USA), and P value < 0.05 was considered
significant in all cases.
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